Diagnostics In Brief
This article was originally published in The Gray Sheet
Executive Summary
Genzyme pharmacogenomics: Firm announces availability of its KRAS gene mutation analysis test to help identify 15%-30% of non-small cell lung cancer tumors unlikely to respond to treatment with drugs Tarceva (Genentech) or Iressa (AstraZeneca). The test, available only through Genzyme's lab, joins two other assays in the firm's portfolio that can conversely detect improved response rates to those drugs based on mutations in the epidermal growth factor receptor gene (1"The Gray Sheet" Oct. 3, 2005, In Brief). "This important convergence of diagnostics and therapeutics is a priority for the company," Genzyme says...
You may also be interested in...
Abbott Diagnostics Unit Teams Up With Big Pharma On Companion Test
Abbott's molecular diagnostics business announced March 7 a collaboration with Genentech, Roche and OSI Pharmaceuticals to develop a gene test that helps select patients more likely to respond to the lung cancer drug Tarceva
Abbott Diagnostics Unit Teams Up With Big Pharma On Companion Test
Abbott's molecular diagnostics business announced March 7 a collaboration with Genentech, Roche and OSI Pharmaceuticals to develop a gene test that helps select patients more likely to respond to the lung cancer drug Tarceva
CDC Grants Spark Development Of Faster Flu Tests
Several companies are working hard this spring and summer to develop diagnostics to accurately test patients for newly emerging dangerous flu strains and differentiate them from more garden variety versions within 30 minutes